The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Osteopontin is a marker for cancer aggressiveness and patient survival
Open accessAbstract
BACKGROUND: Only a fraction of molecular cancer markers identified in the scientific literature have found clinical use. Specifically, few predictors of invasiveness are established in diagnostics. Meta-analysis is a valuable tool for biomarker validation. Here, we evaluate Osteopontin as a marker for tumor aggressiveness (grade, stage, early progression) and patient survival. METHODS: Publications through 2008 with the keywords 'osteopontin AND cancer' were retrieved. Titles and abstracts were screened for studies presenting original data on human subjects. This left 228 publications for data extraction. We applied categorical data analysis for testing the relationship between Osteopontin and a clinical variable. RESULTS: Osteopontin ranks correlated with lower overall and disease-free/relapse-free survival in all tumors combined, as well as in lung cancer, breast cancer, prostate cancer, head and neck cancer, and liver cancer. Further, Osteopontin levels correlated with tumor grade and stage for all tumors combined and for several individual tumor types. Osteopontin levels were significantly associated with the early progression of eight cancers, independent in one, and inversely correlated in two. CONCLUSIONS: Osteopontin is significantly associated with survival in several forms of cancer. Osteopontin levels are also markers for stage, grade, and early tumor progression in multiple cancers, reflecting a common molecular underpinning for distinct clinical measures. Osteopontin has value as a clinical tumor progression marker.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comparing effect sizes in follow-up studies: ROC Area, Cohen's d, and r.
Rice, M. E., & Harris, G. T. (2005) · Law and Human Behavior · doi:10.1007/s10979-005-6832-7 · Cited by 1,608 · cited 1×
“…feature used to quantify this characteristic is the area under the curve, which can be interpreted here as the probability that for two randomly chosen samples, the one with the higher Osteopontin rank will also have a higher rank for the clinical variable in question (Rice and Harris, 2005).”
Cited by
Wei, J., Marisetty, A., Schrand, B., Gabrusiewicz, K., Hashimoto, Y., Ott, M., Grami, Z., Kong, L.-Y., Ling, X., Caruso, H., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121266 · Cited by 396
Metadata
- Authors
- Weber, G. F., Lett, G. S., & Haubein, N. C.
- Venue
- British Journal of Cancer
- Published
- 2010-09
- Volume
- 103
- Issue
- 6
- Pages
- 861-869
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2027230614
- Cited by
- 190
- References
- 1
- FWCI
- 9.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Osteopontin is a marker for cancer aggressiveness and patient survival. https://app.cochat.ai/papers/10.1038/sj.bjc.6605834
- The paper
- Weber, G. F., Lett, G. S., & Haubein, N. C. (2010). Osteopontin is a marker for cancer aggressiveness and patient survival. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6605834
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.